These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 7595233)

  • 1. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
    Hara I; Takechi Y; Houghton AN
    J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor immunity and autoimmunity induced by immunization with homologous DNA.
    Weber LW; Bowne WB; Wolchok JD; Srinivasan R; Qin J; Moroi Y; Clynes R; Song P; Lewis JJ; Houghton AN
    J Clin Invest; 1998 Sep; 102(6):1258-64. PubMed ID: 9739060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.
    Naftzger C; Takechi Y; Kohda H; Hara I; Vijayasaradhi S; Houghton AN
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14809-14. PubMed ID: 8962137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coupling and uncoupling of tumor immunity and autoimmunity.
    Bowne WB; Srinivasan R; Wolchok JD; Hawkins WG; Blachere NE; Dyall R; Lewis JJ; Houghton AN
    J Exp Med; 1999 Dec; 190(11):1717-22. PubMed ID: 10587362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
    Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma.
    Hirschowitz EA; Leonard S; Song W; Ferris B; Leopold PL; Lewis JJ; Bowne WB; Wang S; Houghton AN; Crystal RG
    Gene Ther; 1998 Jul; 5(7):975-83. PubMed ID: 9813669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A melanosomal membrane protein is a cell surface target for melanoma therapy.
    Takechi Y; Hara I; Naftzger C; Xu Y; Houghton AN
    Clin Cancer Res; 1996 Nov; 2(11):1837-42. PubMed ID: 9816138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
    Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
    Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple pathways to tumor immunity and concomitant autoimmunity.
    Turk MJ; Wolchok JD; Guevara-Patino JA; Goldberg SM; Houghton AN
    Immunol Rev; 2002 Oct; 188():122-35. PubMed ID: 12445286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
    Engelhard VH; Bullock TN; Colella TA; Sheasley SL; Mullins DW
    Immunol Rev; 2002 Oct; 188():136-46. PubMed ID: 12445287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.
    Rausch MP; Irvine KR; Antony PA; Restifo NP; Cresswell P; Hastings KT
    J Immunol; 2010 Sep; 185(5):2828-35. PubMed ID: 20668223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune etiology of generalized vitiligo.
    Le Poole IC; Luiten RM
    Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc receptors are required in passive and active immunity to melanoma.
    Clynes R; Takechi Y; Moroi Y; Houghton A; Ravetch JV
    Proc Natl Acad Sci U S A; 1998 Jan; 95(2):652-6. PubMed ID: 9435247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
    Bronte V; Apolloni E; Ronca R; Zamboni P; Overwijk WW; Surman DR; Restifo NP; Zanovello P
    Cancer Res; 2000 Jan; 60(2):253-8. PubMed ID: 10667570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
    J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
    Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
    Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.
    Boross P; Jansen JH; van Tetering G; Nederend M; Brandsma A; Meyer S; Torfs E; van den Ham HJ; Meulenbroek L; de Haij S; Leusen JH
    Immunol Lett; 2014 Aug; 160(2):151-7. PubMed ID: 24613852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
    Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.